Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cell-based therapy for heart failure.

Kai C Wollert1, Helmut Drexler

  • 1Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.

Current Opinion in Cardiology
|April 8, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RHOT Proteins Link Mitochondrial Motility to Cardiomyocyte Sarcomere Maturation.

Circulation research·2026
Same author

Macrophage-specific circular RNA circHIPK2, inflammation, and fibrosis after myocardial infarction.

European heart journal·2026
Same author

Extracellular BRICK1 drives heart repair after myocardial infarction in mice.

Science translational medicine·2026
Same author

Iron regulatory proteins secure iron availability in skeletal muscle to preserve exercise tolerance in heart failure.

Cardiovascular research·2025
Same author

Mitotane treatment of adrenocortical carcinoma induces tumoural secretion of GDF-15: impact on poor prognosis and impaired responsiveness to immunotherapy.

European journal of endocrinology·2025
Same author

Cysteine-rich with EGF-like domains 2 (CRELD2) is an endoplasmic reticulum stress-inducible angiogenic growth factor promoting ischemic heart repair.

Nature cardiovascular research·2024
Same journal

An integrative approach to patient selection for mitral transcatheter edge-to-edge repair in secondary mitral regurgitation.

Current opinion in cardiology·2026
Same journal

Rebooting blood vessel repair: implications of the SEMA-VR CardioLink-15 trial.

Current opinion in cardiology·2026
Same journal

Advancements in wearable technology for heart failure patients.

Current opinion in cardiology·2026
Same journal

Minimally invasive approaches to coronary artery bypass grafting: techniques, current evidence, and future directions.

Current opinion in cardiology·2026
Same journal

Advances in artificial intelligence for the evaluation of mitral regurgitation.

Current opinion in cardiology·2026
Same journal

Role of nutritional interventions to reduce cardiometabolic disease burden in the community.

Current opinion in cardiology·2026
See all related articles

Stem cell therapy shows potential for heart failure but is still experimental. Current methods using bone marrow cells or skeletal myoblasts show limited efficacy and potential risks, requiring further research for true cardiac regeneration.

Area of Science:

  • Cardiovascular Research
  • Regenerative Medicine
  • Stem Cell Biology

Background:

  • Chronic heart failure (CHF) is a major cause of hospitalization with a poor prognosis.
  • Existing treatments for CHF do not address the disease's root cause.
  • Experimental data suggest stem cells may benefit the failing heart through transdifferentiation or paracrine effects.

Purpose of the Study:

  • To review early cell therapy studies in heart failure patients.
  • To assess the suitability of different stem/progenitor cells and delivery methods.
  • To evaluate the potential of cell therapy for cardiac repair.

Main Methods:

  • Review of early clinical trials using distinct stem and progenitor cell populations.
  • Analysis of cell delivery methods in heart failure patients.

Related Experiment Videos

  • Examination of autologous bone marrow cells and skeletal myoblasts in trials.

    • Main Results:

    • Early studies explored stem cell suitability and delivery feasibility for cardiac repair.
    • Bone marrow cells and skeletal myoblasts were predominantly used.
    • Reported improvements in systolic function and tissue viability, but safety concerns (arrhythmogenicity) exist.
    • Small patient numbers and lack of randomization limit efficacy conclusions.

    Conclusions:

    • Cell therapy for heart failure is in its early stages.
    • Current clinical studies suggest feasibility but lack conclusive efficacy data.
    • Bone marrow cells and skeletal myoblasts do not promote true tissue regeneration.
    • Further research into cells with cardiac transdifferentiation capacity is essential.